|
rs121913530
|
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
BEFREE |
Although this mutation in KRAS accounts for 11% of all KRAS mutations in cancer, it is the most prominent KRAS mutant in lung cancer suggesting that G12C-specific inhibitors may provide a new approach for treating the subset of lung cancer patients harboring this mutant allele.
|
30366101 |
2019 |
|
rs121913530
|
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
BEFREE |
We developed an integrative pharmacogenomics analysis to identify potential drug targets to overcome MEK/ERK inhibitor resistance in lung cancer cell lines with KRAS(G12C) mutation (n = 12).
|
31668570 |
2019 |
|
rs121913530
|
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
BEFREE |
Adding mTOR and IGF1R inhibitors to ARS-1620 greatly improves its effectiveness on KRAS-G12C mutant lung cancer cells in vitro and in mouse models.
|
31534020 |
2019 |
|
rs121913530
|
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
BEFREE |
To substantiate these results, an allitinib-sensitive lung cancer-derived cell line (H292) was transfected with plasmids carrying the two most common activating KRAS mutations (p.G12D and p.G12S).
|
26920031 |
2016 |
|
rs121913530
|
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
BEFREE |
Since hypoxic microenvironments select for tumor cells with diminished therapeutic response, we investigated whether hypoxia unequally increases resistance to 3-BrPA in wt p53 MelJuso melanoma harbouring (Q61L)-mutant NRAS and wt BRAF, C8161 melanoma with (G12D)-mutant KRAS (G464E)-mutant BRAF, and A549 lung carcinoma with a KRAS (G12S)-mutation.
|
27863474 |
2016 |
|
rs121913530
|
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
BEFREE |
Next generation sequencing performed on the Ion Torrent platforms by the Ion Ampliseq Colon and Lung Cancer panel showed a similar genomic profile in both neoplastic sites with a concurrent KRAS G12C mutation.
|
25900221 |
2015 |
|
rs121913530
|
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
BEFREE |
Gene-expression profiles in lung cancer cell lines and surgically resected lung AC revealed that KRAS-G12C mutants had an epithelial to mesenchymal transition and a KRAS-independent phenotype.
|
25170638 |
2014 |
|
rs121913530
|
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
BEFREE |
Our study demonstrated that TRAIL significantly suppressed cell survival, by inducing apoptosis in a dose-dependent manner, in the pancreatic cancer BxPC-3 (wild type G12) and lung cancer A549 (G12S) cell lines.
|
20848283 |
2011 |
|
rs121913530
|
|
Carcinoma of lung
|
|
0.880 |
GeneticVariation
|
UNIPROT |
|
|
|
|
rs121913530
|
|
Carcinoma of lung
|
A |
0.880 |
CausalMutation
|
CLINVAR |
|
|
|
|
rs121913529
|
|
Juvenile Myelomonocytic Leukemia
|
|
0.820 |
GeneticVariation
|
BEFREE |
We report on an infant with JMML with somatic KRAS G12A mutation and monosomy 7 who achieved sustained remission following azacitidine monotherapy.
|
31250550 |
2019 |
|
rs121913529
|
|
Juvenile Myelomonocytic Leukemia
|
|
0.820 |
GeneticVariation
|
BEFREE |
In the present study, we report 2 patients with somatic mosaicism for oncogenic NRAS mutations (G12D and G12S) associated with the development of JMML.
|
22753870 |
2012 |
|
rs121913529
|
|
Juvenile Myelomonocytic Leukemia
|
A |
0.820 |
CausalMutation
|
CLINVAR |
KRAS(G12V) enhances proliferation and initiates myelomonocytic differentiation in human stem/progenitor cells via intrinsic and extrinsic pathways.
|
21169357 |
2011 |
|
rs121913529
|
|
Juvenile Myelomonocytic Leukemia
|
T |
0.820 |
CausalMutation
|
CLINVAR |
KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.
|
19358724 |
2009 |
|
rs121913529
|
|
Juvenile Myelomonocytic Leukemia
|
A |
0.820 |
CausalMutation
|
CLINVAR |
KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.
|
19358724 |
2009 |
|
rs121913529
|
|
Juvenile Myelomonocytic Leukemia
|
A |
0.820 |
CausalMutation
|
CLINVAR |
Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
|
19047918 |
2009 |
|
rs121913529
|
|
Juvenile Myelomonocytic Leukemia
|
T |
0.820 |
CausalMutation
|
CLINVAR |
Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
|
19047918 |
2009 |
|
rs121913529
|
|
Juvenile Myelomonocytic Leukemia
|
T |
0.820 |
CausalMutation
|
CLINVAR |
Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia.
|
17910045 |
2008 |
|
rs121913529
|
|
Juvenile Myelomonocytic Leukemia
|
|
0.820 |
GeneticVariation
|
UNIPROT |
Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations.
|
17332249 |
2007 |
|
rs121913529
|
|
Juvenile Myelomonocytic Leukemia
|
A |
0.820 |
CausalMutation
|
CLINVAR |
Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations.
|
17332249 |
2007 |
|
rs121913529
|
|
Juvenile Myelomonocytic Leukemia
|
A |
0.820 |
CausalMutation
|
CLINVAR |
Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome.
|
17704260 |
2007 |
|
rs121913529
|
|
Juvenile Myelomonocytic Leukemia
|
T |
0.820 |
CausalMutation
|
CLINVAR |
Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations.
|
17332249 |
2007 |
|
rs121913529
|
|
Juvenile Myelomonocytic Leukemia
|
T |
0.820 |
CausalMutation
|
CLINVAR |
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
|
15696205 |
2005 |
|
rs121913529
|
|
Juvenile Myelomonocytic Leukemia
|
A |
0.820 |
CausalMutation
|
CLINVAR |
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
|
15696205 |
2005 |
|
rs121913529
|
|
Juvenile Myelomonocytic Leukemia
|
T |
0.820 |
CausalMutation
|
CLINVAR |
Somatic PTPN11 mutations in childhood acute myeloid leukaemia.
|
15842656 |
2005 |